摘要 |
2067758 9110650 PCTABS00006 According to the invention there is provided a compound of formula (I): R1-O(CH2)mA(CH2)nXR or a pharmaceutically acceptable salt thereof, wherein R1 is a group of formula (a or b) where Z is -(CH2)2-, -CH=CH-, -CH2-S- or -CH2-O-; R is a group of formula (c, d or Het) and A is a group of formula (e, f or g) in which the N atom is attached to the group (CH2)n; m is 1 or 2; n is an integer of from 1 to 4; p is 1, 2 or 3; R2 and R3 are each independently hydrogen, C1-C4 alkyl, hydroxy-(C1-C4 alkyl), hydroxy, C1-C4 alkoxy, halo, trifluoromethyl, nitro, cyano, sulphamoyl, -CO(C1-C4 alkyl), -OCO(C1-C4 alkyl), carboxy, -CO2(C1-C4 alkyl), -(CH2)qCONR4R5, -(CH2)qOCONR4R5, -(CH2)qNR6R7 or -NHSO2NH2 in which R4 and R5 are each independently H or C1-C4 alkyl, q is 0, 1 or 2, and either R6 and R7 are each independently H or C1-C4 alkyl or R6 is hydrogen and R7 is -SO2(C1-C4 alkyl), -CO(C1-C4 alkyl) or -CONH(C1-C4 alkyl); X is a direct link, O or S; Y and Y1 are each independently O or CH2; and Het is pyridyl, pyrazinyl or thienyl. The compounds are useful as muscarinic receptor antagonists, particularly in the treatment of irritable bowel syndrome.
|